In Canada, the Quebec government, Investissement Quebec, the Institutnational de la recherche scientifique (INRS), Laval Technopole and the City of Laval have established the City of Biotechnology and Human Health of Metropolitan Montreal. The various organizations said that C$250 million ($162.8 million) will be invested over five years to set up Biotech City, which will have "numerous specialized centers for research, learning, commercial development, incubating new businesses and accommodating biotech and biopharmaceutical companies."
Pierre Lapointe, executive director of the INRS, said that the wealth of expertise in Biotech City "could benefit an industry that is booming and bring in the knowledge capital and human resources necessary to its expansion and consolidation."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze